ArticleDrug delivery and translational research2026
A self-unfolding polymer foil loaded with a permeation enhancer Ionogel for superior oral peptide delivery.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide drugs have gained considerable attention as new molecular entities, due to their high target specificity. However, oral delivery of peptides remains a major challenge, and current formulation approaches typically achieve only low single-digit bioavailability, prompting exploration of synergistic strategies to improve absorption. In this work, a self-unfolding foil device, designed for unidirectional drug release in close proximity to the intestinal mucosa, is combined with a potent permeation enhancer-based ionogel formulation for exploitation of synergies from two different oral delivery approaches. The choline decanoate ionogel is loaded into the foil, and insulin release optimized through hydrophilic surface modification and tailored cavity design. In vivo evaluation in rats demonstrate a bioavailability of 12.5% and a biopotency of 20% relative to subcutaneous administration representing approximately three- and four-fold increases, respectively, compared with the formulation control group. These findings demonstrate that unidirectional release from an advanced drug delivery system can markedly enhance formulation performance and pave the way for further development of similar combinatorial delivery strategies. Overall, this study reports the highest insulin bioavailability achieved with the self-unfolding foil platform to date, and among the highest reported in literature, highlighting its promise for advancing oral peptide delivery in future preclinical studies.
Indexed as
Identifiers
42489819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.